Prospects of siponimod in secondary progressive multiple sclerosis

被引：2
|
作者：
McGinley, Marisa [1 ]
Fox, Robert J. [1 ]
机构：
[1] Cleveland Clin, 9500 Euclid Ave,U-10, Cleveland, OH 44120 USA
来源：
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS | 2018年 / 11卷
关键词：
D O I：
10.1177/1756286418788013
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
    Gajofatto, Alberto
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3153 - 3157
  • [22] Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
    Regner-Nelke, Liesa
    Pawlitzki, Marc
    Willison, Alice
    Rolfes, Leoni
    Oezalp, Sinem-Hilal
    Nelke, Christopher
    Koelsche, Tristan
    Korsen, Melanie
    Grothe, Matthias
    Groppa, Sergiu
    Luessi, Felix
    Engel, Sinah
    Nelles, Gereon
    Bonmann, Eckhard
    Roick, Holger
    Friedrich, Anke
    Knorn, Philipp
    Landefeld, Harald
    Biro, Zoltan
    Ernst, Michael
    Bayas, Antonios
    Menacher, Martina
    Akgun, Katja
    Kleinschnitz, Christoph
    Ruck, Tobias
    Ziemssen, Tjalf
    Pul, Refik
    Meuth, Sven G.
    [J]. NEUROLOGICAL RESEARCH AND PRACTICE, 2022, 4 (01):
  • [23] Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications
    Spiezia, Antonio Luca
    Scalia, Giulia
    Petracca, Maria
    Caliendo, Daniele
    Moccia, Marcello
    Fiore, Antonia
    Cerbone, Vincenza
    Lanzillo, Roberta
    Brescia Morra, Vincenzo
    Carotenuto, Antonio
    [J]. JOURNAL OF NEUROLOGY, 2024, 271 (07) : 4281 - 4291
  • [24] Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series
    Chang, Edward H.
    Hardy, Todd A.
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2024, 389
  • [25] Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients
    Kuhle, Jens
    Kropshofer, Harald
    Barro, Christian
    Meinert, Rolf
    Haring, Dieter A.
    Leppert, David
    Tomic, Davorka
    Dahlke, Frank
    Kappos, Ludwig
    [J]. NEUROLOGY, 2018, 90
  • [26] MODELLING LONG-TERM HEALTH BENEFITS OF SIPONIMOD IN ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN PORTUGAL
    Silva, C.
    Bandeiras, C.
    Laires, P. A.
    [J]. VALUE IN HEALTH, 2020, 23 : S627 - S627
  • [27] Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
    Cortesi, Paolo Angelo
    Antonazzo, Ippazio Cosimo
    Gasperini, Claudio
    Nica, Mihaela
    Ritrovato, Daniela
    Mantovani, Lorenzo Giovanni
    [J]. PLOS ONE, 2022, 17 (03):
  • [28] Treatment of secondary progressive multiple sclerosis - Current recommendations and future prospects
    Rice, GPA
    [J]. BIODRUGS, 1999, 12 (04) : 267 - 277
  • [29] Efficacy of Siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis
    Gold, R.
    Kappos, L.
    Bar-Or, A.
    Vermersch, P.
    Giovannoni, G.
    Fox, R.
    Rouyrre, N.
    Karlsson, G.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 380 - 381
  • [30] AMASIA study: Real World Insights on Siponimod Treated Patients with Secondary Progressive Multiple Sclerosis in Germany
    Hoffmann, O.
    Schreiber, H.
    Klotz, L.
    Weber, M.
    Rauser, B.
    Baufeld, C.
    Ziemssen, T.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 351 - 351
12345